New combo therapy aims to stall leukemia before symptoms start
NCT ID NCT02518555
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tested whether the drug ibrutinib, combined with standard vaccines, can delay disease progression in people with early-stage, high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have no symptoms yet. Forty-two participants received ibrutinib and vaccines to see if the treatment could keep the cancer from getting worse. The goal was to find a better way to manage the disease before it becomes active.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.